

Adriana Ammassari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2530594/publications.pdf>

Version: 2024-02-01

148
papers

7,030
citations

81900

39
h-index

62596

80
g-index

149
all docs

149
docs citations

149
times ranked

6713
citing authors

#	ARTICLE	IF	CITATIONS
1	Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 171.	7.4	1,076
2	Self-Reported Symptoms and Medication Side Effects Influence Adherence to Highly Active Antiretroviral Therapy in Persons With HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 28, 445-449.	2.1	405
3	Correlates and Predictors of Adherence to Highly Active Antiretroviral Therapy: Overview of Published Literature. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 31, S123-S127.	2.1	390
4	Depressive Symptoms, Neurocognitive Impairment, and Adherence to Highly Active Antiretroviral Therapy Among HIV-Infected Persons. <i>Psychosomatics</i> , 2004, 45, 394-402.	2.5	231
5	Diagnosis of AIDS-related focal brain lesions. <i>Neurology</i> , 1997, 48, 687-694.	1.1	214
6	Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). <i>Aids</i> , 2002, 16, 369-379.	2.2	189
7	Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. <i>Aids</i> , 2001, 15, 1483-1491.	2.2	175
8	Value of Combined Approach With Thallium-201 Single-Photon Emission Computed Tomography and Epstein-Barr Virus DNA Polymerase Chain Reaction in CSF for the Diagnosis of AIDS-Related Primary CNS Lymphoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 554-554.	1.6	167
9	Clinical Epidemiology and Survival of Progressive Multifocal Leukoencephalopathy in the Era of Highly Active Antiretroviral Therapy: Data from the Italian Registry Investigative Neuro AIDS (IRINA). <i>Journal of NeuroVirology</i> , 2003, 9, 47-53.	2.1	157
10	Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. <i>Blood</i> , 2002, 100, 1984-1988.	1.4	156
11	Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. <i>Aids</i> , 2008, 22, 1759-1767.	2.2	141
12	Prevalence, Associated Factors, and Prognostic Determinants of AIDS-Related Toxoplasmic Encephalitis in the Era of Advanced Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2004, 39, 1681-1691.	5.8	131
13	Evaluation of cerebrospinal fluid EBV-DNA and IL-10 as markers for <i>in vivo</i> diagnosis of AIDS-related primary central nervous system lymphoma. <i>British Journal of Haematology</i> , 1995, 90, 844-849.	2.5	121
14	Patient-Reported Nonadherence to HAART Is Related to Protease Inhibitor Levels. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2000, 24, 123-128.	2.1	120
15	Reduced Rate of Diagnostic Positive Detection of JC Virus DNA in Cerebrospinal Fluid in Cases of Suspected Progressive Multifocal Leukoencephalopathy in the Era of Potent Antiretroviral Therapy. <i>Journal of Clinical Microbiology</i> , 2005, 43, 4175-4177.	3.9	118
16	Minimally Invasive Diagnosis of Acquired Immunodeficiency Syndrome-Related Primary Central Nervous System Lymphoma. <i>Journal of the National Cancer Institute</i> , 1998, 90, 364-369.	6.3	117
17	Cross-Resistance among Nonnucleoside Reverse Transcriptase Inhibitors Limits Recycling Efavirenz after Nevirapine Failure. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 835-838.	1.1	117
18	The Effect of Potent Antiretroviral Therapy and JC Virus Load in Cerebrospinal Fluid on Clinical Outcome of Patients with AIDS-Associated Progressive Multifocal Leukoencephalopathy. <i>Journal of Infectious Diseases</i> , 2000, 182, 1077-1083.	4.0	113

#	ARTICLE	IF	CITATIONS
19	AIDS-related focal brain lesions in the era of highly active antiretroviral therapy. <i>Neurology</i> , 2000, 55, 1194-1200.	1.1	111
20	Variable Prediction of Antiretroviral Treatment Outcome by Different Systems for Interpreting Genotypic Human Immunodeficiency Virus Type 1 Drug Resistance. <i>Journal of Infectious Diseases</i> , 2003, 187, 1934-1943.	4.0	96
21	Epstein-Barr Virus Infection Is Predictive of CNS Involvement in Systemic AIDS-Related Non-Hodgkin's Lymphomas. <i>Journal of Clinical Oncology</i> , 2000, 18, 3325-3330.	1.6	92
22	PCR detection of <i>Toxoplasma gondii</i> DNA in CSF for the differential diagnosis of AIDS-related focal brain lesions. <i>Journal of Medical Microbiology</i> , 1996, 45, 472-476.	1.8	72
23	Cidofovir added to HAART improves virological and clinical outcome in AIDS-associated progressive multifocal leukoencephalopathy. <i>Aids</i> , 2000, 14, F117-F121.	2.2	72
24	Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes. <i>European Journal of Haematology</i> , 1999, 63, 77-85.	2.2	71
25	Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era. <i>Journal of NeuroVirology</i> , 2001, 7, 323-328.	2.1	68
26	Reliability and Clinical Relevance of the HIV-1 Drug Resistance Test in Patients With Low Viremia Levels. <i>Clinical Infectious Diseases</i> , 2014, 58, 1156-1164.	5.8	67
27	Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. <i>Aids</i> , 2001, 15, 1579-1581.	2.2	67
28	Patient-Reported Nonadherence to HAART Is Related to Protease Inhibitor Levels. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2000, 24, 123-128.	2.1	65
29	Treatment-Related Factors and Highly Active Antiretroviral Therapy Adherence. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 31, S128-S131.	2.1	65
30	Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: Extended follow-up of an observational study. <i>Journal of NeuroVirology</i> , 2001, 7, 364-368.	2.1	64
31	Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of <i>Pneumocystis carinii</i> pneumonia and toxoplasmic encephalitis. <i>Aids</i> , 1995, 9, 1343-1350.	2.2	62
32	Patient-reported and physician-estimated adherence to HAART. <i>Journal of General Internal Medicine</i> , 2004, 19, 1104-1110.	2.6	60
33	Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens. <i>Aids</i> , 2003, 17, 1099-1102.	2.2	58
34	Diagnosis of <i>Pneumocystis carinii</i> pneumonia: Specificity and sensitivity of polymerase chain reaction in comparison with immunofluorescence in bronchoalveolar lavage specimens. <i>Journal of Medical Microbiology</i> , 1993, 38, 449-453.	1.8	57
35	Clinical and Virological Monitoring During Treatment with Intrathecal Cytarabine in Patients with AIDS-Associated Progressive Multifocal Leukoencephalopathy. <i>Clinical Infectious Diseases</i> , 1999, 28, 624-628.	5.8	55
36	Improved detection of JC virus DNA in cerebrospinal fluid for diagnosis of AIDS-related progressive multifocal leukoencephalopathy. <i>Journal of Clinical Microbiology</i> , 1996, 34, 1343-1346.	3.9	49

#	ARTICLE	IF	CITATIONS
37	Changing Disease Patterns in Focal Brain Lesion-Causing Disorders in AIDS. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998, 18, 365-371.	0.3	46
38	Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study. <i>Aids</i> , 2000, 14, 1660-1662.	2.2	42
39	Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients. <i>Annals of Internal Medicine</i> , 2017, 166, 9.	3.9	41
40	Discontinuation of Secondary Prophylaxis for <i>Pneumocystis carinii</i> Pneumonia in Human Immunodeficiency Virus-Infected Patients: A Randomized Trial by the CIOP Study Group. <i>Clinical Infectious Diseases</i> , 2003, 36, 645-651.	5.8	39
41	Experience with brain biopsy in acquired immune deficiency syndrome-related focal lesions of the central nervous system. <i>British Journal of Surgery</i> , 2005, 81, 1508-1511.	0.3	38
42	Epstein-Barr virus in monitoring the response to therapy of acquired immunodeficiency syndrome-related primary central nervous system lymphoma. <i>Annals of Neurology</i> , 1999, 45, 259-261.	5.3	37
43	Highly Active Antiretroviral Therapy Reduces the Age-Associated Risk of Dementia in a Cohort of Older HIV-1-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 386-392.	1.1	37
44	Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. <i>Aids</i> , 1998, 12, 473-480.	2.2	35
45	Impact of Pre-Therapy Viral Load on Virological Response to Modern First-Line Haart. <i>Antiviral Therapy</i> , 2013, 18, 867-876.	1.0	34
46	UPLC-MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1073, 183-190.	2.3	34
47	Self-Reported Sexual Dysfunction Is Frequent Among HIV-Infected Persons and Is Associated with Suboptimal Adherence to Antiretrovirals. <i>AIDS Patient Care and STDs</i> , 2008, 22, 291-299.	2.5	33
48	Beyond Virological Suppression: The Role of Adherence in the Late Haart Era. <i>Antiviral Therapy</i> , 2012, 17, 785-792.	1.0	33
49	Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. <i>Clinical Microbiology and Infection</i> , 2016, 22, 288.e1-288.e8.	6.0	33
50	Relative Prognostic Value of Self-Reported Adherence and Plasma Nrti/Pi Concentrations to Predict Virological Rebound in Patients Initially Responding to Haart. <i>Antiviral Therapy</i> , 2004, 9, 291-296.	1.0	32
51	Self-Reported Nonadherence with Antiretroviral Drugs Predicts Persistent Condition. <i>HIV Clinical Trials</i> , 2001, 2, 323-329.	2.0	31
52	Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2372-2378.	3.0	30
53	Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers. <i>PLoS ONE</i> , 2017, 12, e0173893.	2.5	30
54	Impact of metabolic complications on antiretroviral treatment adherence: Clinical and public health implications. <i>Current HIV/AIDS Reports</i> , 2009, 6, 121-129.	3.1	29

#	ARTICLE	IF	CITATIONS
55	Simple and rapid two-step polymerase chain reaction for diagnosis of <i>Pneumocystis carinii</i> infection. <i>Journal of Clinical Microbiology</i> , 1993, 31, 2788-2789.	3.9	27
56	Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature. <i>BMC Infectious Diseases</i> , 2017, 17, 182.	2.9	25
57	Granulocytic Myeloid-Derived Suppressor Cells Increased in Early Phases of Primary HIV Infection Depending on TRAIL Plasma Level. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 575-582.	2.1	25
58	Disease progression and poor survival of AIDS-associated progressive multifocal leukoencephalopathy despite highly active antiretroviral therapy. <i>Aids</i> , 1998, 12, 1937-8.	2.2	25
59	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. <i>New Microbiologica</i> , 2012, 35, 113-59.	0.1	25
60	Timed Short Messaging Service Improves Adherence and Virological Outcomes in HIV-1-Infected Patients With Suboptimal Adherence to Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 58, e113-e115.	2.1	24
61	HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1865-1873.	3.0	23
62	Discrepancies between physician's perception of depression in HIV patients and self-reported CES-D-20 assessment: the DHIVA study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016, 28, 147-159.	1.2	22
63	Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1056-1062.	3.0	22
64	Rate of CD4 ⁺ Cell Count Increase over Periods of Viral Load Suppression: Relationship with the Number of Previous Virological Failures. <i>Clinical Infectious Diseases</i> , 2010, 51, 456-464.	5.8	21
65	Inconsistent condom use among HIV-positive women in the "Treatment as Prevention Era" data from the Italian DIDI study. <i>Journal of the International AIDS Society</i> , 2013, 16, 18591.	3.0	21
66	Macrophage chemoattractant protein-1 levels in cerebrospinal fluid correlate with containment of JC virus and prognosis of acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. <i>Journal of NeuroVirology</i> , 2005, 11, 219-224.	2.1	20
67	In HIV/HCV co-infected patients T regulatory and myeloid-derived suppressor cells persist after successful treatment with directly acting antivirals. <i>Journal of Hepatology</i> , 2017, 67, 422-424.	3.7	20
68	Sexual dysfunction in HIV infection. <i>Lancet, The</i> , 2007, 369, 905-906.	13.7	19
69	Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy. <i>BMC Public Health</i> , 2018, 18, 870.	2.9	19
70	Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014. <i>HIV Medicine</i> , 2019, 20, 99-109.	2.2	19
71	Comparison of Demand for Drugs Used for COVID-19 Treatment and Other Drugs During the Early Phase of the COVID-19 Pandemic in Italy. <i>JAMA Network Open</i> , 2021, 4, e2037060.	5.9	19
72	AIDS-Associated Cerebral Toxoplasmosis: An Update on Diagnosis and Treatment. <i>Current Topics in Microbiology and Immunology</i> , 1996, 219, 209-222.	1.1	19

#	ARTICLE	IF	CITATIONS
73	Antiretroviral treatmentâ€based cost saving interventions may offset expenses for new patients and earlier treatment start. <i>HIV Medicine</i> , 2014, 15, 165-174.	2.2	18
74	Oral human Papillomavirus DNA detection in HIV-positive men: prevalence, predictors, and co-occurrence at anal site. <i>BMC Infectious Diseases</i> , 2018, 18, 25.	2.9	18
75	Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort. <i>Journal of the International AIDS Society</i> , 2014, 17, 19812.	3.0	17
76	Bone Marrow CD34⁺ Progenitor Cells from HIV-Infected Patients Show an Impaired T Cell Differentiation Potential Related to Proinflammatory Cytokines. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 590-596.	1.1	17
77	Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 735-741.	3.0	16
78	Successful prevention of HIV mother-to-child transmission with dolutegravir-based combination antiretroviral therapy in a vertically infected pregnant woman with multiclass highly drug-resistant HIV-1. <i>Aids</i> , 2015, 29, 2534-2537.	2.2	16
79	Primary central nervous system lymphoma and brain biopsy in AIDS. <i>Lancet, The</i> , 1993, 341, 1411-1412.	13.7	15
80	Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000â€14. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2837-2845.	3.0	15
81	Fluconazole for Primary Prophylaxis of AIDS-associated Cryptococcosis: A Case-control Study. <i>Scandinavian Journal of Infectious Diseases</i> , 1995, 27, 235-237.	1.5	14
82	Presumptive Clinical Criteria Versus Endoscopy in the Diagnosis of Candida Esophagitis at Various HIV-1 Disease Stages. <i>Endoscopy</i> , 1995, 27, 371-376.	1.8	14
83	An anal cancer screening program for MSM in Italy: Prevalence of multiple HPV types and vaccine-targeted infections. <i>Journal of Clinical Virology</i> , 2015, 72, 49-54.	3.1	14
84	Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV co-infected patients receiving directly-acting antivirals. <i>PLoS ONE</i> , 2017, 12, e0187095.	2.5	14
85	96 Week Follow-Up of HIV-Infected Patients in Rescue with Raltegravir Plus Optimized Backbone Regimens: A Multicentre Italian Experience. <i>PLoS ONE</i> , 2012, 7, e39222.	2.5	13
86	Induced first abortion rates before and after <scp>HIV</scp> diagnosis: results of an Italian selfâ€administered questionnaire survey carried out in 585 women living with <scp>HIV</scp>. <i>HIV Medicine</i> , 2013, 14, 31-39.	2.2	13
87	Central nervous system penetrationâ€effectiveness rank does not reliably predict neurocognitive impairment in HIVâ€infected individuals. <i>Journal of the International AIDS Society</i> , 2014, 17, 19655.	3.0	13
88	Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. <i>Aids</i> , 2015, 29, 193-200.	2.2	13
89	Firstâ€line antiretroviral therapy with efavirenz plus tenofovir disoproxil fumarate/emtricitabine or rilpivirine plus tenofovir disoproxil fumarate/emtricitabine: a durability comparison. <i>HIV Medicine</i> , 2018, 19, 475-484.	2.2	13
90	Liver stiffness reduction and serum fibrosis score improvement in HIV/hepatitis C virus-coinfected patients treated with direct-acting antivirals. <i>HIV Medicine</i> , 2018, 19, 578-584.	2.2	13

#	ARTICLE	IF	CITATIONS
91	Circulating Levels and <i>Vivo</i> Production of β^2 -Chemokines, Interferon β^3 , and Interleukin 2 in Advanced Human Immunodeficiency Virus Type 1 Infection: The Effect of Protease Inhibitor Therapy. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 835-843.	1.1	12
92	Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 189-194.	2.5	12
93	HIV-Specific CD8 T Cells Producing CCL-4 Are Associated With Worse Immune Reconstitution During Chronic Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 338-344.	2.1	12
94	Clinical Epidemiology and Survival of Progressive Multifocal Leukoencephalopathy in the Era of Highly Active Antiretroviral Therapy: Data from the Italian Registry Investigative Neuro AIDS (IRINA). <i>Journal of NeuroVirology</i> , 2003, 9, 47-53.	2.1	12
95	Bone marrow CD34+ progenitor cells may harbour HIV-DNA even in successfully treated patients. <i>Clinical Microbiology and Infection</i> , 2015, 21, 290.e5-290.e8.	6.0	11
96	Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. <i>Clinical Microbiology and Infection</i> , 2017, 23, 267.e1-267.e4.	6.0	11
97	Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts \leq 200 cells/mm ³ and HIV-RNA \geq 5 log ₁₀ copies/mL. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2732-2741.	3.0	11
98	Benefits and risks of switching from protease inhibitors to nevirapine with stable background therapy in patients with low or undetectable viral load: a multicentre study. <i>Aids</i> , 2000, 14, 1655-1656.	2.2	11
99	Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART. <i>Antiviral Therapy</i> , 2004, 9, 291-6.	1.0	11
100	Three-Year Clinical Outcomes of Resistance Genotyping and Expert Advice: Extended follow-up of the Argenta Trial. <i>Antiviral Therapy</i> , 2006, 11, 321-327.	1.0	11
101	Evaluation of different staging systems for Kaposi's sarcoma in HIV-infected patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 1992, 118, 635-636.	2.5	10
102	Oral lesions in HIV and HCV infected individuals in HAART era. <i>Journal of Oral Pathology and Medicine</i> , 2008, 37, 468-474.	2.7	10
103	A Randomized Trial Comparing the Introduction of Ritonavir or Indinavir in 1251 Nucleoside-Experienced Patients with Advanced HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1809-1820.	1.1	9
104	Relationship between body mass index and bone mineral density in HIV-infected patients referred for DXA. <i>Journal of the International AIDS Society</i> , 2014, 17, 19569.	3.0	9
105	Nosocomial Infection Rates in an Italian Intensive Care Unit Using the National Nosocomial Infection Surveillance System. <i>Infection Control and Hospital Epidemiology</i> , 2001, 22, 132-133.	1.8	8
106	Italian consensus statement on paediatric HIV infection. <i>Infection</i> , 2010, 38, 301-319.	4.7	8
107	Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 72, dkw512.	3.0	8
108	Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1637-1642.	3.0	8

#	ARTICLE	IF	CITATIONS
109	IL-18 and Stem Cell Factor affect hematopoietic progenitor cells in HIV-infected patients treated during primary HIV infection. <i>Cytokine</i> , 2018, 103, 34-37.	3.2	8
110	Development and validation of an HPLC-UV method for quantification of elvitegravir and two other new antiretrovirals, dolutegravir and rilpivirine, in the plasma of HIV-positive patients. <i>Biomedical Chromatography</i> , 2018, 32, e4274.	1.7	8
111	Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3460-3470.	3.0	8
112	Comparison of two medications in central nervous system toxoplasmosis in patients with AIDS. <i>Italian Journal of Neurological Sciences</i> , 1992, 13, 475-479.	0.1	7
113	Italian Consensus Statement on Management of HIV-Infected Individuals with Advanced Disease Na ⁻ ve to Antiretroviral Therapy. <i>Infection</i> , 2009, 37, 270-82.	4.7	7
114	Chronic HIV-Infected Patients Show an Impaired Dendritic Cells Differentiation of Bone Marrow CD34+ Cells. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, 342-344.	2.1	7
115	Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy. <i>HIV Medicine</i> , 2016, 17, 471-478.	2.2	7
116	A new procedure to analyze polymorphonuclear myeloid derived suppressor cells in cryopreserved samples cells by flow cytometry. <i>PLoS ONE</i> , 2018, 13, e0202920.	2.5	7
117	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 628-639.	3.0	7
118	Prevalence of Prolonged Amenorrhea in HIV-Infected Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 61, e19-e21.	2.1	6
119	Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3085-3094.	3.0	6
120	Genotypic Tropism Testing in HIV-1 Proviral DNA Can Provide Useful Information at Low-Level Viremia. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2935-2941.	3.9	6
121	Early ART in primary HIV infection may also preserve lymphopoiesis capability in circulating haematopoietic progenitor cells: a case report. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1598-1600.	3.0	6
122	Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study. <i>BMC Infectious Diseases</i> , 2016, 16, 401.	2.9	6
123	Vitamin D deficiency is associated with neurocognitive impairment in HIV-infected subjects. <i>Infection</i> , 2019, 47, 929-935.	4.7	6
124	Randomized clinical trial on efficacy of fixed-dose efavirenz/tenofovir/emtricitabine on alternate days versus continuous treatment. <i>Aids</i> , 2019, 33, 493-502.	2.2	6
125	Epstein-Barr virus in monitoring the response to therapy of acquired immunodeficiency syndrome-related primary central nervous system lymphoma. <i>Annals of Neurology</i> , 1999, 45, 259-61.	5.3	6
126	Immune Status and Serial Quantiferon-TB Gold In-Tube Screening for Latent <i>Mycobacterium tuberculosis</i> Infection Among HIV-Infected Persons in a Country With a Low Tuberculosis Incidence. <i>Journal of Infectious Diseases</i> , 2015, 211, 1852-1853.	4.0	5

#	ARTICLE	IF	CITATIONS
127	Prevalence and Associated Factors of Neurocognitive Impairment in HIV-Positive Patients on Effective Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Treatment. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 907-908.	1.1	5
128	Immunological Aspects of Patients with HIV-1 Disease following Immunization with Recombinant gp160 (VaxSyn). <i>Antibiotics and Chemotherapy</i> , 1996, 48, 147-154.	0.5	4
129	Identifying Risk of Viral Failure in Treated HIV-Infected Patients Using Different Measures of Adherence: The Antiretroviral Therapy Cohort Collaboration. <i>Journal of Clinical Medicine</i> , 2018, 7, 328.	2.4	4
130	Proportion and factors associated with recent HIV infection in a cohort of patients seen for care in Italy over 1996-2014: Data from the ICONA Foundation Study cohort. <i>PLoS ONE</i> , 2017, 12, e0189045.	2.5	4
131	Timing of Antiretroviral Therapy Initiation after a First AIDS-Defining Event: Temporal Changes in Clinical Attitudes in the ICONA Cohort. <i>PLoS ONE</i> , 2014, 9, e89861.	2.5	3
132	Acute HIV infection (AHI) in a specialized clinical setting: case-finding, description of virological, epidemiological and clinical characteristics. <i>Journal of the International AIDS Society</i> , 2014, 17, 19676.	3.0	3
133	The Different Roles of Interleukin 7 and Interleukin 18 in Affecting Lymphoid Hematopoietic Progenitor Cells and CD4 Homeostasis in Naive Primary and Chronic HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2016, 63, 1683-1684.	5.8	3
134	Detection of <i>T.gundii</i> -DNA by PCR in AIDS-related toxoplasmic encephalitis. <i>Journal of Eukaryotic Microbiology</i> , 1996, 43, 118S-119S.	1.7	2
135	Liver fibrosis stage predicts early treatment outcomes with peginterferon plus ribavirin in HIV/hepatitis C virus co-infected patients. <i>Aids</i> , 2004, 18, 1602-1604.	2.2	2
136	Evidence of Dual Sexual Transmission of Multi-resistant HIV with Two Years Persistence of Resistance to NRTI and NNRTI: a Case Report. <i>Infection</i> , 2008, 36, 178-180.	4.7	2
137	Randomized trial of DRV/r or LPV/r QD monotherapy vs maintaining a PI/r-based antiretroviral regimen in persons with suppressed HIV replication. <i>Journal of the International AIDS Society</i> , 2014, 17, 19809.	3.0	2
138	Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis. <i>Journal of the International AIDS Society</i> , 2014, 17, 19802.	3.0	2
139	Plasma trough concentrations of antiretrovirals in HIV-infected persons treated with direct-acting antiviral agents for hepatitis C in the real world. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 160-164.	3.0	2
140	Virological and Immunological Outcomes of an Intensified Four-Drug versus a Standard Three-Drug Antiretroviral Regimen, Both Integrase Strand Transfer Inhibitor-Based, in Primary HIV Infection. <i>Pharmaceuticals</i> , 2022, 15, 403.	3.8	2
141	Low-dose dapsone, co-trimoxazole, and survival in <i>Pneumocystis carinii</i> primary prophylaxis. <i>Aids</i> , 1996, 10, 1046-1047.	2.2	1
142	Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 481-490.	2.1	1
143	HIV-1 infection and progressive multifocal leukoencephalopathy in a person without detectable HIV antibodies. <i>Aids</i> , 1998, 12, 1251-1253.	2.2	1
144	Long-term follow-up of HIV-infected patients in salvage therapy with raltegravir plus optimized background regimens: a multicentre Italian experience. <i>Journal of the International AIDS Society</i> , 2010, 13, P38.	3.0	0

#	ARTICLE	IF	CITATIONS
145	Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy. <i>Journal of the International AIDS Society</i> , 2014, 17, 19775.	3.0	0
146	APRI and FIB-4 scores are not associated with neurocognitive impairment in HIV-infected persons. <i>Journal of the International AIDS Society</i> , 2014, 17, 19658.	3.0	0
147	Association of Sofosbuvir and Daclatasvir Plasma Trough Concentrations with Patient-, Treatment-, and Disease-Related Factors Among HIV/HCV-Coinfected Persons. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2022, 47, 135-142.	1.6	0
148	Slow or fast viral load decay as a predictor of residual viremia level in HIV-infected patients undergoing successful first-line cART. <i>New Microbiologica</i> , 2017, 40, 234-241.	0.1	0